Select Page

Press Releases

Sign up to get full access to all our latest Press Releases

Rapid Dose Therapeutics Enters Supplier and Purchase Agreement with a Leading Gas and Convenience Store Retailer for Nutraceutical and Vitamin Products

September 23, 2022


BURLINGTON, Ontario – September 23, 2022 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company focused on health and wellness leveraging an innovative, proprietary oral delivery platform today announced that they have entered into a supplier and purchase agreement...

Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order

September 12, 2022


BURLINGTON, Ontario – September 12, 2022 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release dated August 29, 2022, the Company and its auditors are continuing to...

Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update

August 25, 2022


Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update  BURLINGTON, Ontario – August 25, 2022: Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is providing a bi-weekly default status update in accordance with National Policy...

Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update

August 11, 2022


Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update BURLINGTON, Ontario – August 11, 2022: Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is providing a bi-weekly default status update in accordance with National Policy...

Rapid Dose Therapeutics Announces Closing of First Tranche of Private Placement

August 10, 2022


Rapid Dose Therapeutics Announces Closing of First Tranche of Private Placement  BURLINGTON, Ontario – August 10, 2022: Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, today announced that it has closed on $230,000 in...

Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update

July 28, 2022


Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update BURLINGTON, Ontario – July 28, 2022: Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is providing a bi-weekly default status update in accordance with National Policy...

Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update

July 13, 2022


Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update BURLINGTON, Ontario – July 13, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is providing a bi-weekly default status update in accordance with National Policy 12-203...

Rapid Dose Therapeutics Announces Issuance of Management Cease Trade Order

June 30, 2022


BURLINGTON, Ontario – June 30, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, announces that, further to its press release dated June 16, 2022 (the “Default Announcement”), at the request of the Company, the...

Rapid Dose Therapeutics Announces Delay in Filing Annual Financial Statements

June 16, 2022


Rapid Dose Therapeutics Announces Delay in Filing Annual Financial Statements BURLINGTON, Ontario – June 16, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, announces that it will not be in a position to file...

Rapid Dose Therapeutics Corp Announces Proposed Private Placement

May 26, 2022


BURLINGTON, Ontario – May 26, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, today announced that it plans to complete a private placement financing (the “Financing”) for up to $5,000,000 of gross proceeds, consisting...

1 2 3 4 5 6 7 8 9 10